641 related articles for article (PubMed ID: 15604213)
61. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
62. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
[TBL] [Abstract][Full Text] [Related]
63. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
Pamir N; Lynn FC; Buchan AM; Ehses J; Hinke SA; Pospisilik JA; Miyawaki K; Yamada Y; Seino Y; McIntosh CH; Pederson RA
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E931-9. PubMed ID: 12540373
[TBL] [Abstract][Full Text] [Related]
64. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
[TBL] [Abstract][Full Text] [Related]
65. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
66. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue.
Oben J; Morgan L; Fletcher J; Marks V
J Endocrinol; 1991 Aug; 130(2):267-72. PubMed ID: 1919397
[TBL] [Abstract][Full Text] [Related]
67. Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice.
Degerman E; Manganiello V; Holst JJ; Ahrén B
Eur J Pharmacol; 2004 Sep; 498(1-3):319-23. PubMed ID: 15364011
[TBL] [Abstract][Full Text] [Related]
68. Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans.
Filipsson K; Tornøe K; Holst J; Ahrén B
J Clin Endocrinol Metab; 1997 Sep; 82(9):3093-8. PubMed ID: 9284750
[TBL] [Abstract][Full Text] [Related]
69. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
70. Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Yokoyama H; Haneda M
Front Endocrinol (Lausanne); 2020; 11():214. PubMed ID: 32390941
[No Abstract] [Full Text] [Related]
71. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
Irwin N; McClean PL; Cassidy RS; O'harte FP; Green BD; Gault VA; Harriott P; Flatt PR
Diabetes Metab Res Rev; 2007 Oct; 23(7):572-9. PubMed ID: 17315241
[TBL] [Abstract][Full Text] [Related]
72. Effect of GIP and GLP-1 antagonists on insulin release in the rat.
Tseng CC; Zhang XY; Wolfe MM
Am J Physiol; 1999 Jun; 276(6):E1049-54. PubMed ID: 10362617
[TBL] [Abstract][Full Text] [Related]
73. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
Omar B; Ahrén B
Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
[TBL] [Abstract][Full Text] [Related]
74. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
75. Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice.
Pacini G; Ahrén B
Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28611149
[TBL] [Abstract][Full Text] [Related]
76. Peptidergic regulation of maturation of the stimulus-secretion coupling in fetal islet beta cells.
Sjöholm A; Sandberg E; Ostenson CG; Efendić S
Pancreas; 2000 Apr; 20(3):282-9. PubMed ID: 10766455
[TBL] [Abstract][Full Text] [Related]
77. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
78. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
[TBL] [Abstract][Full Text] [Related]
79. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
[TBL] [Abstract][Full Text] [Related]
80. Insulin and intracellular calcium responsiveness to glucagon-like peptide-1 and pituitary adenylate cyclase-activating peptide by dispersed adult porcine islet cells.
Davalli AM; Bertuzzi F; Meoni C; Scaglia L; Socci C; Pozza G; Pontiroli AE
Transplantation; 1999 Jan; 67(1):174-6. PubMed ID: 9921815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
